摘要
目的探讨培门冬酶联合吉西他滨治疗结外NK/T细胞淋巴瘤的疗效及安全性。方法结外NK/T细胞淋巴瘤患者54例分为CHOPL组25例和培门冬酶联合吉西他滨组(联合组)29例。CHOPL组给予CHOP加左旋门冬酰胺酶,联合组为培门冬酶联合吉西他滨、奥沙利铂、地塞米松治疗。比较2组治疗有效率及副作用。结果 54例患者的总有效率为88.9%。CHOPL组有效率为84%,联合组有效率为93.1%,差异无统计学意义(χ2=1.127,P=0.289)。CHOPL组患者消化道反应、高血糖、过敏反应的发生率均高于联合组(P<0.05)。结论培门冬酶联合吉西他滨对结外NK/T细胞淋巴瘤的近期治疗效果较好安全性高。
Objective To explore the efficacy and safety of PEG – asparaginase combined with gemxibine in treatment of patients with extra-nodal NK / T-cell lymphoma. Methods A total of54 patients with extra-nodal NK / T-cell lymphoma were divided into CHOPL group treated by CHOP combined with L-asparaginase（ n = 25） and combined group treated by PEG-asparaginase combined with gemxibine,oxaliplatine and dexamisone（ n = 29）. The effective rate and adverse reactions were compared between two groups. Results The total effective rate was 88. 9% in all the patients. The effective rates were 84% in the CHOPL group and 93. 1% in the combined group,and there was no significant difference between two groups（ χ2= 1. 127,P = 0. 289）. The incidence rates of complications such as gastrointestinal reaction, hyperglycemia and anaphylactic reaction in the CHOPL group were significantly higher than those in the combined group（ P〈0. 05）. Conclusion PEG-asparaginase combined with gemxibine is effective and safe for treatment of patients with extra-nodal NK / T-cell lymphoma.
出处
《实用临床医药杂志》
CAS
2015年第11期19-22,共4页
Journal of Clinical Medicine in Practice
